Clinical trial NCT03576521: Evaluation of Ocoxin®-Viusid® in Breast Cancer
Official title: Efficacy of Ocoxin-Viusid in the Prevention of Acute Toxicity by Chemotherapy in Patients With Breast Cancer. Phase II Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Cancer
Breast Carcinoma
Adriamycin Toxicity
Cyclosporine Toxicity
Keywords: breast cancer
chemotherapy toxicity
Oxidative Stress
Nutritional supplement
Ocoxin Viusid
Lead sponsor: Catalysis SL
Sponsor class: INDUSTRY
First posted: 2018-07-03
Enrollment: 120
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Phase II randomized, controlled, double blind clinical trial.
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose is to determine the efficacy of the nutritional supplement Ocoxin-Viusid oral solution (OV) in the reduction of acute toxicity of Chemotherapy (CT) treatment with patients with breast carcinoma. A randomized, double-blind phase II clinical trial was designed, with a sample of 120 patients distributed in 2 arms: 60 patients will receive the CT treatment plus the OV, 60 will receive CT plus OV placebo. The OV / placebo will be administered before, during and 3 weeks after the conclusion of the CT. A better tolerance to the treatment is expected with the addition of the nutritional supplement.

Detailed description: To obtain the sample size, the proportion of patients presenting adverse reactions that require interrupting chemotherapy treatment will be taken into account. In the institution, this figure is close to 15%. Since it is a dietary supplement, with extensive information on the safety of the product, the design is used in a stage of Flemming (without early stop rules). Assuming that the Ocoxin-Viusid product would clearly be declared ineffective (maximal ineffectiveness) if the proportion of patients not presenting adverse reactions was equal to less than 85% (p0), that is the maximum level of success below which the product does not shows signs of efficacy (the study does not guarantee further research) and taking a p1 value of 95%, where p1 is the minimum level of efficacy required from which the product would be declared effective (the results guarantee to continue a study phase III). Assuming an α error of 5% (probability of rejecting the null hypothesis when it is true) and β (probability of rejecting the alternative hypothesis when it is true) of 20% (the power of the test: 1 - β = 80%), It is determined to recruit a maximum number of 59 - 60 subjects. Determine a = 54, where a is the number of responses equal and below which the product is declared ineffective (H0 is accepted). And r = a + 1 is the cut-off point, that is, the number of responses from which the efficacy level ensures to continue to a phase III study. In this case we would expect to obtain a number of successes ≥ 55.

Patients will be randomized after surgery, in the chemotherapy consultation, and once they meet the established inclusion criteria. In order to achieve the masking of the research product, these have been labeled by a balanced randomized list obtained by computer, which will be in the possession of the Biostatistician of the study of the Clinical Investigations Section of INOR and the promoter. The product under study has been consecutively labeled from 1 to 120 (60 patients in each therapeutic arm).

Eligibility criteria: Inclusion Criteria:

1. Patients who have undergone surgery and histologically confirm a breast carcinoma and who are subject to adjuvant treatment with AC chemotherapy at the time of inclusion in the trial.
2. Patients with age ≥18 years of female sex.
3. General health status according to the Karnofsky Index ≥ 70.
4. Laboratory parameters within the normal limits defined to receive this chemotherapy including normal Echocardiogram:

   to. Hematopoietic: Hemoglobin ≥ 9 g / L, Total Leukocytes ≥ 3 x 109 cells / L, Neutrophils ≥ 1.5 x 109 cells / L, Platelets ≥ 100 x 109 / L.

   b. Hepatic: Liver function within 2.5 times upper normal limit and without liver disease demonstrated by TGP, OGT and alkaline phosphatase.

   c. Renal function: creatinine ≤ 132 μmol / l.
5. Patients who express written voluntariness to enter the study with their signature of the informed consent document.
6. Patients of childbearing age with negative pregnancy test or who have effective contraceptive methods such as intrauterine devices, hormonal contraceptives, barrier method or tubal ligation.

Exclusion Criteria:

1. Patients who have received prior chemotherapy.
2. Patients who are receiving another research product.
3. Patients with known hypersensitivity to any ingredient of the investigational product.
4. Decompensated intercurrent diseases, including: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hepatic diseases and psychiatric illnesses that could limit adherence to the requirements of the clinical trial or any other special condition that at the discretion of the physician put your health or life at risk during your participation in the trial.
5. Pregnancy, lactation or puerperium.
6. Patients with cerebral metastases and / or leptomeningeal carcinosis.
7. Patients with a second concomitant tumor.
8. Patients carrying the human immunodeficiency virus (HIV).

Primary outcomes:
measure: The Ocoxin-Viusid effect in the treatment with chemotherapy
timeFrame: 4 months
measure: Compliance with the planned chemotherapy schedule
timeFrame: 4 months
measure: The Ocoxin-Viusid effect in the treatment with chemotherapy
timeFrame: 4 months
Secondary outcomes:
measure: Evaluation of Quality of Life
timeFrame: 4 months
measure: Evaluation of Quality of Life
timeFrame: 4 months
measure: Evaluation of Quality of Life
timeFrame: 4 months
measure: Evaluation of nutritional status
timeFrame: 4 months
measure: Evaluation of nutritional status
timeFrame: 4 months
measure: Side effects of the treatment
timeFrame: 4 months
Other outcomes:
Locations:
city: La Habana
country: Cuba
facility: National Institute of Oncology and Radiobiology (INOR)
Study officials:
References: